Shattuck Labs
Yahoo Finance • 3 days ago
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial for SL-325 in Q3 2... Full story
Yahoo Finance • 12 days ago
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change SolarMax Technology Inc. 215,178,273 2.50 1.57 2.025 +1.095 LOBO EV TECH... Full story
Yahoo Finance • 12 days ago
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents from aggregate pro... Full story
Yahoo Finance • 5 months ago
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily recep... Full story
Yahoo Finance • 5 months ago
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the recept... Full story
Yahoo Finance • 6 months ago
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptor... Full story
Yahoo Finance • 2 years ago
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
AUSTIN, TX & DURHAM, NC, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medic... Full story
Yahoo Finance • 2 years ago
Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript
Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript November 10, 2023 Operator: Good morning and welcome to the Shattuck Labs Third Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only m... Full story
Yahoo Finance • 2 years ago
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights
– Positive interim data from Phase 1B clinical trial of SL-172154in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC) demonstrated an acceptable safety profile and encouraging anti-tumor act... Full story
Yahoo Finance • 2 years ago
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic med... Full story
Yahoo Finance • 2 years ago
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting
– SL-172154 as monotherapy and in combination with azacitidine demonstrates anti-leukemic activity and an acceptable safety and tolerability profile – AUSTIN, Texas and DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc.... Full story
Yahoo Finance • 2 years ago
The Rosen Law Firm, P.A. Announces Proposed Securities Class Action Settlement on Behalf of Purchasers of the Common Stock of Shattuck Labs, Inc. - STTK
BROOKLYN, N.Y., July 11, 2023 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the United States District Court for the Eastern District of New York has approved the following announcement of a proposed securities class action... Full story
Yahoo Finance • 2 years ago
Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights
— Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) to be presented at the 2023 American Society of Clinical Oncology (ASCO) annual meeting in June – — Dosed first patients... Full story
Yahoo Finance • 2 years ago
Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference
AUSTIN, TX and DURHAM, NC, April 03, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic me... Full story
Yahoo Finance • 2 years ago
Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting
– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease – AUSTIN, TX and DURHAM, NC, March 16, 2023 (GL... Full story
Yahoo Finance • 2 years ago
Shattuck Labs Announces Participation in Upcoming March Conferences
AUSTIN, TX and DURHAM, NC, March 01, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic me... Full story
Yahoo Finance • 2 years ago
Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer – – Dosed patients in first combination cohort with azacitidine in ongoing Phase 1A/B clinic... Full story
Yahoo Finance • 3 years ago
Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023
AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medic... Full story
Yahoo Finance • 3 years ago
Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference
AUSTIN, TX & DURHAM, NC, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medic... Full story
Yahoo Finance • 3 years ago
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023
AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medic... Full story
